Enhanced induction of apoptosis in chronic myeloid leukemia cells through synergistic effect of telomerase inhibitor MST-312 and imatinib
Molecular Biology Reports · 2024
DOI: 10.1007/s11033-024-10074-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Najibe Karami und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran. Hauptthemen laut MEDLINE: Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Telomerase, Apoptosis. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Kerman University of Medical Sciences.
Abstract (Originalsprache)
BACKGROUND: Chronic Myeloid Leukemia (CML), accounting for 15-20% of adult leukemia cases, is marked by the Philadelphia chromosome, resulting from the t(9;22)(q34;q11) translocation. This leads to uncontrolled cell proliferation and survival. Imatinib therapy lowers BCR-ABL levels, influencing telomere-associated proteins and increasing telomerase accessibility, indirectly boosting its activity. This study investigates the effects of MST-312 and imatinib, both individually and combined, on a CML cell line. METHODS: The K562 cells were subjected to different doses of MST-312 and imatinib, including four combination concentrations. Cell viability and metabolic activity were measured using trypan blue and MTT assays at 24-, 36-, and 48-h post-treatment. Flow cytometry (AnnexinV/PI) assessed cell apoptosis after 36 h of treatment with MST-312 and imatinib, both individually and in combination. The expression levels of Bax, Bcl-2, hTERT, P21, P53, and c-Myc were determined via qRT-PCR. RESULTS: Both MST-312 and imatinib independently reduced cell viability in a dose- and time-dependent manner. Their combination further decreased cell viability compared to monotherapy. Treatment of K562 cells with MST-312 and imatinib for 36 h increased Bax expression and the Bax/Bcl-2 ratio while decreasing Bcl-2 expression. Combined treatment significantly reduced hTERT ansd P21 gene expression compared to imatinib alone. CONCLUSIONS: The combination of MST-312 and imatinib shows potential as a CML therapy. However, further research and clinical trials are necessary to validate these findings and determine their clinical relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran.
- Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Science, Tehran, Iran.
- Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of Medical Sciences, Kerman, Iran.
- Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran. ahmad.fatemi2@gmail.com.
Förderung
- Kerman University of Medical Sciences
Zitieren
APA
Karami, N., Navidinia, A. A., Ehsan, M., Farsinejad, A., & Fatemi, A. (2024). Enhanced induction of apoptosis in chronic myeloid leukemia cells through synergistic effect of telomerase inhibitor MST-312 and imatinib. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-10074-x
Vancouver
Karami N, Navidinia AA, Ehsan M, Farsinejad A, Fatemi A. Enhanced induction of apoptosis in chronic myeloid leukemia cells through synergistic effect of telomerase inhibitor MST-312 and imatinib. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-10074-x
BibTeX
@article{Karami2024,
author = {Karami, Najibe and Navidinia, Amir Abbas and Ehsan, Mohsen and Farsinejad, Alireza and Fatemi, Ahmad},
title = {Enhanced induction of apoptosis in chronic myeloid leukemia cells through synergistic effect of telomerase inhibitor MST-312 and imatinib},
journal = {Molecular Biology Reports},
year = {2024},
doi = {10.1007/s11033-024-10074-x}
}
EUVIMED